Business Description
Kiora Pharmaceuticals is a US-based company focused on developing treatments for serious eye diseases, with operations also in Austria and Australia. Its most advanced drug candidate, KIO-301, is currently in Phase 2 trials and aims to restore vision in patients suffering from inherited retinal conditions such as retinitis pigmentosa and Stargardt disease. The company has additional treatments in earlier stages of development targeting inflammatory eye conditions. Kiora works with partners including Théa Open Innovation and Global Genes to advance its pipeline and reach patients with rare ocular disorders.
